Palm for the treatment of chemotherapy-induced peripheral neuropathy incidental to the treatment of cancer

A method for the treatment or prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in a cancer patient treated with, or to be treated with, a chemotherapeutic agent causing CIPN, the method comprising:

• administering a therapeutically effective amount of a composition containing a peptide amphiphile lipid micelle (PALM) nanoparticle to the cancer patient, the PALM nanoparticle comprising a PALM containing the chemotherapeutic agent causing CIPN, and wherein the PALM comprises:
• a) i) a peptide, wherein the peptide in the PALM comprises the amino acid sequences:
• X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20 wherein:
• X1 is the amino acid D;
• X2 and X20 are each the amino acid V or Aib;
• X3, X6, X10 and X13 are each an amino acid independently selected from the group consisting of L and F;
• X4, X12 and X19 are each the amino acid Q;
• X5 is an amino A or Aib;
• X7, X16 and X18 are each the amino acid K;
• X8 and X15 are each the amino acid E;
• X9 and X14 are each an amino acid independently selected from the group consisting of A, L, F and Aib;
• X11 is an amino acid selected from the group consisting of A, Aib and N;
• and X17 is an amino acid selected from the group consisting of W, F and L;
• or
• a) ii) a peptide, wherein the peptide in the PALM comprises the amino acid sequences:
• X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20, wherein:
• X1 is an amino acid selected from the group consisting of D and E;
• X2 and X20 are each an amino acid independently selected from the group consisting of V, Aib, I, and L;
• X3, X6, X10 and X13 are each an amino acid independently selected from the group consisting of L, I, V, W, Y, Aib, Amv and F;
• X4, X12 and X19 are each an amino acid independently selected from the group consisting of Q and N;
• X5, X16 and X18 are each an amino acid independently selected from the group consisting of K, R, H and Orn;
• X7 is selected from the group consisting of A, G, S, V, Aib, and Amv;
• X8 and X15 are independently selected from the group consisting of the amino acid E and D;
• X9 and X14 are an amino acid independently selected from the group consisting of A, G, S L, F, V, Amv, and Aib;
• X11 is an amino acid selected from the group consisting of A, G, S, Aib, Amv, V and N;
• and X17 is an amino acid selected from the group consisting of W, F, Y, I, V, and L, (SEQ ID NO:24), wherein the peptide is optionally acylated at the N-terminus, amidated at the C-terminus, or both acylated at the N-terminus and amidated at the C-terminus and the peptide is from 20 to 24 amino acid in length;
• b) a lipid component comprising sphingomyelin and one or more additional phospholipids;
• and
• c) a cargo molecule that is a compound conjugate having the formula (I):
• A—R—L—X (formula I)
• wherein A is an agent having a hydroxyl or an amine group;
• R is the hydroxyl or the amine group of the agent;
• L is a linker;
• and X is an anchor moiety.